louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01164319: "UNMASKING Study" For Atrial Fibrillation Recurrences Typing in Early Postoperative Period
Official title: Typing of the Atrial Fibrillation Recurrences in Early Postoperative Period After Pulmonary Veins Isolation Through Continous Subcutaneous Monitoring.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Percutaneous continous monitoring
ablation
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2010-07-16
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to identify the most appropriate method for managing patients with AF recurrences after the first ablation procedure, through the diagnostic data stored by a subcutaneous AF monitor.


Eligibility criteria: Inclusion Criteria:

* highly symptomatic patients refractory to at least two antiarrhythmic drugs
* patients with sustained PAF episodes and/or history of PersAF interrupted with cardioversion.

Exclusion Criteria:

* congestive heart failure
* ejection fraction \<35%
* left atrial diameter \>60 mm
* previous ablation procedure

Primary outcomes:
measure: Freedom from atrial fibrillation or atrial flutter/tachycardia in Group 4 vs Group 3
timeFrame: 12 months
Secondary outcomes:
measure: Freedom from AF in each group and the comparison of any group to each other
timeFrame: 12 months
Other outcomes:
Locations:
city: Novosibirsk
country: Russian Federation
facility: State Research Institute of CIrculation Pathology
Study officials:
affiliation: State Research Institute of Circulation Pathology
name: Evgeny A Pokushalov, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N, Karaskov A. Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):823-31. doi: 10.1161/CIRCEP.111.964809. Epub 2011 Sep 19.
Clinical trial NCT06225219: Establishing the Chaplain Role in a Primary Care Clinic Setting
Official title: Establishing the Chaplain Role in a Primary Care Clinic Setting
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Emotional Disorder
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2024-01-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient at the GCAC who are \> 18 years old

• Met with a member of the on-staff chaplaincy during a visit to GCAC

Brief summary: In 2019, a full-time chaplain was placed in the Golden Cross Academic Clinic (GCAC), with the chaplain's focus being in the primary care internal medicine department. While research exists regarding chaplains in the inpatient setting, research regarding the presence of a full-time chaplain in a primary care setting as well as the topics patients discuss with that chaplain are limited.

Detailed description: A few studies conducted in the hospital setting have shown what topics patients typically discuss with a chaplain. In the article, "Patients and Loved Ones' Expectations of Chaplain Services. Munchausen and colleagues present that the two highest-rated services performed by chaplains were spiritual and emotional support. This study also found that patients wanted to see a chaplain for the following reasons: to be listened to, to be with in times of anxiety, to offer support to loves ones, to remind of God's care and presence, to pray, for religious rituals, to assist with the understanding of advance care planning documents, and to counsel regarding moral or ethical decisions.

Eligibility criteria: Inclusion Criteria:

* • Patient at the GCAC who are \> 18 years old

  * Met with a member of the on-staff chaplaincy during a visit to GCAC

Exclusion Criteria:

* • Patient did not meet with a member of the on-staff chaplaincy during a visit to GCAC

Primary outcomes:
measure: Number of times chaplain is requested by patient or provider
timeFrame: 1 year
measure: Usefulness, feasibility, and reception of screening mechanism for GCAC staff
timeFrame: 1 year
measure: Themes discussed during meeting between chaplain and patient
timeFrame: 1 year
measure: Number of meetings/conversations pertaining to each theme identified
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
affiliation: Methodist Midlothian Medical Center
name: Andrew Dowden, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02558218: Postoperative Discomfort and Ocular Redness Following Phacoemulsification Surgery
Official title: Postoperative Discomfort and Ocular Redness Following Phacoemulsification and Intraocular Lens Implantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Lead sponsor: Democritus University of Thrace
Sponsor class: OTHER
First posted: 2015-09-23
Enrollment: 80
Sex: ALL
Minimum age (years): 55
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Primary objective of the study is the assessment of the patients' discomfort and ocular redness following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.

Detailed description: Participants will be recruited from the Cataract Service of the University Hospital of Alexandroupolis (UHA) in a consecutive-if-eligible basis. By means of a custom computer randomization program all participants will randomly populate either study group (who will receive Systane Ultra as additional postoperative treatment) and control group (who will receive standard postoperative treatment).

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale

Exclusion Criteria:

1. Endothelial cell count less than 1900,
2. Glaucoma,
3. IOP-lowering medications,
4. Former incisional surgery,
5. Former diagnosis of corneal disease,
6. Diabetes or autoimmune diseases
7. Former diagnosis of dry eye disease

Primary outcomes:
measure: Foreign body sensation
timeFrame: 1 month postoperatively
Secondary outcomes:
measure: Ocular Redness
timeFrame: 7 days postoperatively
measure: Corneal Sensitivity
timeFrame: 1 month postoperatively
Other outcomes:
Locations:
city: Alexandroupolis
country: Greece
facility: Eye Institute Of thrace
state: Evros
Study officials:
affiliation: Assistant Professor
name: Georgios Labiris, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Labiris G, Ntonti P, Sideroudi H, Kozobolis V. Impact of polyethylene glycol 400/propylene glycol/hydroxypropyl-guar and 0.1% sodium hyaluronate on postoperative discomfort following cataract extraction surgery: a comparative study. Eye Vis (Lond). 2017 May 10;4:13. doi: 10.1186/s40662-017-0079-5. eCollection 2017.
Clinical trial NCT00558818: Long-term Study With Clevudine
Official title: A Phase lV Study to Evaluate the Long-term Safety and Efficacy of Clevudine in the Patients Chronically Infected With Hepatitis B Virus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Hepatitis B
Lead sponsor: Bukwang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2007-11-15
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A open-labeled phase lV study with 96 weeks of treatment period. The purpose of this study is to investigate safety and efficacy of clevudine in patients chronically infected with hepatitis B virus, HBeAg positive or negative.


Eligibility criteria: Inclusion Criteria

* Patient with DNA levels \>=1 x 10\^5 copies/mL within 30 days of baseline.
* Patient is documented to be HBsAg positive for \> 6 months.
* Patient has ALT levels \>=80 IU/L
* Women of childbearing potential must have a negative urine (β-HCG) pregnancy test taken within 14 days of starting therapy.

Exclusion Criteria.

* Patient is currently receiving antiviral, immunomodulatory, cytotoxic or corticosteroid therapy.
* Patients previously treated with interferon within the previous 6 months.
* Patients previously treated with clevudine, lamivudine, adefovir, entecavir, telbivudine or any other investigational nucleoside for HBV infection.
* Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
* Patient is coinfected with HCV, HDV or HIV.
* Patient with clinical evidence of decompensated liver disease or hepatocellular carcinoma
* Patient is pregnant or breast-feeding.
* Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases.
* Patient has a clinically relevant history of abuse of alcohol or drugs.
* Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness that in the investigator's opinion might interfere with therapy.
* Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dL\]) \[Note: multiply estimates by 0.85 for women\]

Primary outcomes:
measure: Proportion of patients with HBV DNA below the assay limit of detection by Real-time PCR
timeFrame: Screening, day1,every 12 weeks during treatment period(96weeks)
Secondary outcomes:
measure: Antiviral activity : change from baseline in HBV DNA (log10 copies/mL)Biochemical improvement (e.g. ALT normalization)Proportion of patients with HBeAg loss and/or seroconversionClevudine-related mutation
timeFrame: Screening, day1, every 12 weeks during treatment period(96 weeks)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: KoreaUniversity Guro Hospital
Study officials:
References:
Clinical trial NCT04883918: ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Official title: Evaluation of Safety and Efficacy of ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Acute-graft-versus-host Disease
Lead sponsor: ASC Therapeutics
Sponsor class: INDUSTRY
First posted: 2021-05-12
Enrollment: 60
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Acute GVHD following allogeneic HCT is an immune-triggered process, leading to profound immune dysregulation and organ dysfunction. Despite pivotal advances, aGVHD is one of the leading causes of non-relapse mortality in patients undergoing HCT.

Placenta-derived DSCs, isolated from the fetal membrane of maternal origin, are a type of stromal cells with well-characterized immunosuppressive properties. The current study is designed to assess the safety and efficacy of 4 intravenous (IV) doses of ASC930 DSC cells in aGVHD patients.


Eligibility criteria: Inclusion Criteria:

* Participants ≥ 2 months of age
* Diagnosis of aGVHD grade II-IV following allogeneic HSCT according to standard criteria (Harris, 2016).
* Diagnosis of SR-aGVHD according to Mohty (2020)
* Meet one of the following criteria:

  * Participants who are Ruxolitinib-refractory, according to Mohty (2020)
  * Participants who are not eligible for SOC therapy
  * Participants who agree to receive ASC930 as a second-line therapy
* Karnofsky/Lansky Performance Status of at least 30 at the time of study entry
* Minor participants must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).

Exclusion Criteria:

* Diagnosis of active Hepatic Sinusoidal Obstruction Syndrome (SOS)
* Presence of an active uncontrolled infection
* Active treatment for a hyprecoagulation disorder
* Evidence of diffuse alveolar hemorrhage or other active pulmonary disease
* Evidence of encephalopathy as defined by a change in mental status since the onset of aGVHD
* Evidence of relapse of malignancy
* Receival of agents other than steroids for primary treatment of aGVHD
* Severe allergic history to cell-based products

Primary outcomes:
measure: Overall Response Rate (ORR) at Day 28
timeFrame: 28 days post-infusion
measure: Number of adverse events, and serious AEs
timeFrame: 30 days post-infusion
Secondary outcomes:
measure: Duration of response (DOR) at DAY 180
timeFrame: 180 days post-infusion
measure: Overall survival (OS) rate at DAY 180
timeFrame: 180 days post-infusion
measure: Complete Response (CR) at Day 28 and Day 180
timeFrame: 28 and 180 days post-infusion
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00310518: Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
Official title: A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cancer
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Sponsor class: INDUSTRY
First posted: 2006-04-04
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to assess the overall response rate (ORR) of persistent, recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.


Eligibility criteria: Inclusion Criteria:

* Able to provide signed and dated informed consent prior to study-specific screening procedures.
* Histologically or cytologically confirmed leiomyosarcoma that is persistent, recurrent or metastatic.
* Measurable disease as defined by RECIST.
* Karnofsky performance status \>= 70%
* Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last infusion of ARQ 501.
* Hemoglobin (Hgb) \>= 10 g/dL.
* Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L (\>= 1,500/mm3).
* Platelet count \>= 100 x 10\^9/L (\>= 100,000/mm3).
* Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) or less than or equal to 3.0 x ULN with metastatic liver disease.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN less than or equal to 5.0 ULN with metastatic liver disease.
* Creatinine less than or equal to 1.5 x ULN.

Exclusion Criteria:

* Received three or more prior anticancer chemotherapy regimens.
* Have active, uncontrolled systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.
* Have received anticancer chemotherapy, immunotherapy, radiotherapy, surgery or investigational agents within four weeks of first infusion.
* Have symptomatic or untreated central nervous system (CNS) involvement.
* Are pregnant or breastfeeding.
* Previous exposure to ARQ 501.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Premiere Oncology of Arizona
state: Arizona
city: Duarte
country: United States
facility: City of Hope Medical Center
state: California
city: Santa Monica
country: United States
facility: Premiere Oncology
state: California
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Philadelphia
country: United States
facility: Pennsylvania Oncology Hematology Associates
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01570218: Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy
Official title: Randomized Clinical Trial Testing Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Uterine Cancer
Ovarian Cancer
Keywords: breast cancer
gynecological cancer
radiotherapy
fatigue
musicotherapy
Lead sponsor: Universidade Federal de Goias
Sponsor class: OTHER
Collaborators: name: Associaçao de Combate ao Cancer em Goias
First posted: 2012-04-04
Enrollment: 164
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: OBJETIVE: To study the influence of musicotherapy in reduction of fatigue related to cancer in patients with breast's or gynecology's cancer, during the radiotherapy treatment.

Detailed description: METHODS: This is a randomized controled study (Control Group - CG e musicotherapy Group - MTG) wich values fatigue, life's quality, anxiety, depression by using evaluative instruments Functional Assessment of Cancer Therapy: Fatigue (FACT-F), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) in three different moments (during first week of radiotherapy, in the intermediate phase's week and during the last week of radiotherapy) for patients of both groups. Women allocated in MTG, in addition to the scales described above, answered the musicotherapy Questionary (MQ), and the Subjective Impression of the Subject's Questionary in last meeting. Musicotherapy sessions were individual and lasted an average of 40 minutes. Music therapeutic techniques used were Musical Audition (MA) and Therapeutic Musical Audition (TMA).

Eligibility criteria: Inclusion Criteria:

* Patients with breast and gynecological cancer with indication for radiotherapy
* Performance status 0,1

Exclusion Criteria:

* Hemoglobin \< 10mg/dl
* Patients in psychotherapy during the study
* Use of antidepressants
* Patients presenting more than one cancer type

Primary outcomes:
measure: Assess the influence of musicotherapy in the reduction of fatigue
timeFrame: 45 days
Secondary outcomes:
measure: Assess the reduction of depression
timeFrame: 45 days
measure: Asses the reduction of anxiety
timeFrame: 45 days
measure: Assess the quality of life
timeFrame: 45 days
Other outcomes:
Locations:
city: Goiania
country: Brazil
facility: Goias Anticancer Association
state: Goias
city: Goiania
country: Brazil
facility: Hospital Araujo Jorge, Associacao de Combate ao Cancer em Goias
state: Goias
Study officials:
affiliation: Universidade Federal de Goias
name: Ruffo Freitas-Junior, PhD
role: STUDY_CHAIR
affiliation: Universidade Federal de Goias
name: Tereza R Alcantara-Silva, Ms Mus
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01240018: ProSat - Long Term Effect of Probiotics on Satiety
Official title: Probiotics and Satiety - Acute Effects and Persistence of Acute Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Appetite Regulation
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2010-11-15
Enrollment: 66
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The aim of the ProSat study is to examine the effects of a probiotic capsule containing Lb. Casei on subjective appetite sensation, ad libitum energy intake, and appetite hormone response in a single meal test and to determine whether the acute effects persist after daily supplementation of the probiotic capsule.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* Normal to slight overweight (BMI: 22-28 kg/m2)
* 20-45 years of age

Exclusion Criteria:

* Smoking
* Daily medicine use (oral contraceptives excluded)
* Use of pre- and probiotic supplements and foods
* Blood donation 3 months prior to the study
* Hb \< 7,5mmol/l
* Chronic illnesses such as hyperlipidemia, diabetes inflammatory diseases
* Pregnancy or breastfeeding
* Elite athletes (\>10 hours hard exercise/week)
* Vegetarians

Primary outcomes:
measure: Glucose, insulin, GLP-1, GLP-2, CCK, PYY, PP, ghrelin, amylin, LPS, TNF-alfa, CRP, fibrinogen.
timeFrame: June 2011
Secondary outcomes:
measure: Subjective appetite measurements, spontaneous food intake.
timeFrame: June 2011
Other outcomes:
Locations:
city: Frederiksberg
country: Denmark
facility: University of Copenhagen, Department of Human Nutrition
state: DK
Study officials:
affiliation: Department of Human Nutrition, Copenhagen University, Denmark
name: Arne Astrup, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01806818: Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients
Official title: A Phase 2, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Compare Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Low Back Pain
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2013-03-07
Enrollment: 98
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multi-center Study to Compare Efficacy and Safety between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients during 7 days.


Eligibility criteria: Inclusion Criteria:

* Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing
* 20≤ age ≤60
* A patient has symptom of acute low back pain
* 4≤ VAS

Exclusion Criteria:

* Subjects who cannot prohibit anti-inflammatory drug, painkiller or muscle relaxants during clinical trial
* Chronic rheumatoid arthritis patients
* Patients having a medical history of hypersensitivity to Eperisone Hydrochloride
* Subject having a hereditary problem such as galactose intolerance, Lapp lactase deficiency, or glucose galatose malabsorption
* Participation in other studies before 60 days of first dosing
* Female patients having positive pregnancy test, lactating women,planning pregnancy during clinical trial
* Inadequate subject for the clinical trial by the investigator's decision

Primary outcomes:
measure: VAS improvement of pain at rest, on movement and at night
timeFrame: 7 days
Secondary outcomes:
measure: Change of Modified Schober test
timeFrame: 7 days
measure: Change of Lateral Body Bending test
timeFrame: 7 days
measure: Change of EuroQol by patients
timeFrame: 7 days
measure: Change of Oswestry Disability Index
timeFrame: 7 days
measure: Overall pain improvement by investigator
timeFrame: at last visit (D7+2)
Other outcomes:
Locations:
city: Anyang
country: Korea, Republic of
facility: Hallym University Sacred Heart Hospital
city: Seoul
country: Korea, Republic of
facility: CHA Bundang Medical Center
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital
city: Seoul
country: Korea, Republic of
facility: Medical college of Yonsei University, Gangnam Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
affiliation: Gangnam Severance Hospital
name: Hak-Sun Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References: